Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Pfizer Says Pivotal Phase 3 BASIS Clinical Trial Of Marstacimab Met Primary Endpoints

Por: RTTNews Health May 30, 2023

thumbnail

Drug major Pfizer Inc. () announced Tuesday that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects.Marstacimab is a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX... + full article



Similar News

FDA Authorizes Bivalent Pfizer Covid Vaccine As Booster Dose For Select Children Under 5

RTTNews USA Health March 15, 2023

thumbnailThe U.S. Food and Drug Administration has authorized bivalent Pfizer-BioNTech covid-19 vaccine as booster dose for certain children 6 months through 4 years of age.In a statement, the regulator said it has amended the emergency use authorization or EUA of the Pfizer-BioNTech... + más

FDA Authorizes Bivalent Pfizer Covid Vaccine As Booster Dose For Select Children Under 5 | RTTNews

Amid pathetic uptake, FDA green lights confusing COVID vaccine update for kids | Ars Technica


FDA Authorizes Bivalent Pfizer Covid Vaccine As Booster Dose For Select Children Under 5

RTTNews USA Health March 15, 2023

thumbnailThe U.S. Food and Drug Administration has authorized bivalent Pfizer-BioNTech covid-19 vaccine as booster dose for certain children 6 months through 4 years of age.In a statement, the regulator said it has amended the emergency use authorization or EUA of the Pfizer-BioNTech... + más

FDA Authorizes Bivalent Pfizer Covid Vaccine As Booster Dose For Select Children Under 5 | RTTNews

Amid pathetic uptake, FDA green lights confusing COVID vaccine update for kids | Ars Technica


G1 Therapeutics To Discontinue Phase 3 PRESERVE 1 Trial

RTTNews USA Health February 13, 2023

thumbnailOncology company G1 Therapeutics, Inc. () announced Monday topline results from its pivotal Phase 3 PRESERVE 1 trial showing that the trial achieved its co-primary endpoints related to severe neutropenia with statistical significance.However, early anti-tumor efficacy data,... + más

How Derek Jeter’s arrival may leave Frank Thomas looking for a new spot in Fox’s MLB lineup | New York Post

Can ADC Therapeutics Strike Gold With Lymphoma Drug Zynlonta? | RTTNews


Fact Check: Were the Grammys sponsored by Pfizer?

Newsweek USA Business February 06, 2023

thumbnailPfizer's involvement with the 2023 Grammy Awards sparked speculation online, with some viewers wondering how much input the pharmaceutical company had.The annual music ceremony was held at the Crypto.com Arena in Los Angeles, California on Sunday night, with Beyoncé... + más

Here's how to watch the 2023 Grammys on iPhone, iPad, Apple TV, and more | 9to5Mac

Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy. | MarketWatch


Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.

MarketWatch USA Business February 04, 2023

thumbnailPfizer stock, too, has fallen out of favor, along with other Covid plays. At $44, it’s down 15% this year, making it one of the worst performers in the index. And it’s 30% below its late 2021 peak, badly trailing the rest of the drug group.   Now looks like the time to buy... + más

Fact Check: Were the Grammys sponsored by Pfizer? | Newsweek

Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history | CNBC


Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history

CNBC USA Health December 06, 2022

thumbnailVials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.Dado Ruvic Reuters has rejected allegations made by rival that its Covid-19 vaccine is a copy, accusing the Boston biotech company of... + más

Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate

Moderna is suing Pfizer over its coronavirus vaccine | The Verge


Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics

CNBC USA Health November 02, 2022

thumbnailPfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021.John Thys AFP Getty Images... + más

Pfizer raises 2022 earnings guidance, beats third-quarter expectations | CNBC

Pfizer climbs on strong Q3 results, raised outlook | MarketWatch



About iurex | Privacy Policy | Disclaimer |